comparemela.com

Latest Breaking News On - Nasdaq rxst - Page 10 : comparemela.com

BTIG Research Boosts RxSight (NASDAQ:RXST) Price Target to $29 00

RxSight (NASDAQ:RXST – Get Rating) had its target price boosted by BTIG Research from $25.00 to $29.00 in a research report released on Monday morning, The Fly reports. Other analysts have also recently issued research reports about the company. Wells Fargo & Company lifted their price target on RxSight from $17.00 to $27.00 in a […]

Wells Fargo & Company Increases RxSight (NASDAQ:RXST) Price Target to $27 00

RxSight (NASDAQ:RXST – Get Rating) had its target price boosted by analysts at Wells Fargo & Company from $17.00 to $27.00 in a note issued to investors on Monday, The Fly reports. Wells Fargo & Company‘s price target would indicate a potential upside of 2.97% from the stock’s previous close. RXST has been the topic […]

Contrasting RxSight (NASDAQ:RXST) & Innovative Eyewear (NASDAQ:LUCY)

RxSight (NASDAQ:RXST – Get Rating) and Innovative Eyewear (NASDAQ:LUCY – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Valuation & Earnings This table compares RxSight and Innovative Eyewear’s […]

RxSight (NASDAQ:RXST) Sees Large Volume Increase

Shares of RxSight, Inc. (NASDAQ:RXST – Get Rating) saw an uptick in trading volume on Thursday . 348,247 shares were traded during mid-day trading, an increase of 129% from the previous session’s volume of 152,393 shares.The stock last traded at $18.15 and had previously closed at $17.42. Wall Street Analyst Weigh In RXST has been […]

RxSight (NASDAQ:RXST) Earns Buy Rating from Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of RxSight (NASDAQ:RXST – Get Rating) in a research note published on Wednesday, Benzinga reports. Needham & Company LLC currently has a $22.00 target price on the stock. Several other research firms have also recently commented on RXST. Oppenheimer started coverage on shares of RxSight […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.